- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.01. | ADALTA LIMITED: AdCella milestones and regulatory progress | - | ASX | ||
| 14.01. | ADALTA LIMITED: East to West webinar presentation - BZDS1901 | - | ASX | ||
| 13.01. | ADALTA LIMITED: Upcoming investor webinar | 2 | ASX | ||
| 13.01. | ADALTA LIMITED: Proposed issue of securities - 1AD | - | ASX | ||
| 13.01. | ADALTA LIMITED: Proposed issue of securities - 1AD | 1 | ASX | ||
| ADALTA Aktie jetzt für 0€ handeln | |||||
| 12.01. | ADALTA LIMITED: Placement raises A$1.2 million | - | ASX | ||
| 09.01. | HotList stocks: Manuka, 4DX, Adalta, and other trending companies in Week 2 | 1 | The Market Herald Australia | ||
| 05.01. | XFRA NEW INSTRUMENTS AVAILABLE ON 05.01.2026 | 303 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.01.2026
Aktien
1 AU0000001AD2 AdAlta Ltd.
2 CA0156071049... ► Artikel lesen | |
| 02.01. | AdAlta inks major CAR-T deal for global development outside China | 4 | smallcaps.com.au | ||
| 01.01. | ADALTA LIMITED: CAR-T collaboration agreement | - | ASX | ||
| 12.12.25 | ADALTA LIMITED: Change in substantial holding | - | ASX | ||
| 11.12.25 | ADALTA LIMITED: Change in substantial holding | - | ASX | ||
| 11.12.25 | ADALTA LIMITED: Change in substantial holding | - | ASX | ||
| 04.12.25 | ADALTA LIMITED: Change in Director Interest Notice (TO, DF &PM) | - | ASX | ||
| 04.12.25 | ADALTA LIMITED: Notification of cessation of securities - 1AD | - | ASX | ||
| 03.12.25 | ADALTA LIMITED: Cleansing Notice | - | ASX | ||
| 03.12.25 | ADALTA LIMITED: Application for quotation of securities - 1AD | - | ASX | ||
| 03.12.25 | ADALTA LIMITED: Application for quotation of securities - 1AD | - | ASX | ||
| 03.12.25 | ADALTA LIMITED: Application for quotation of securities - 1AD | - | ASX | ||
| 03.12.25 | ADALTA LIMITED: $0.78 million FY25 RDTI refund received | - | ASX |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,485 | -2,04 % | Märkte am Morgen: Qiagen, Klöckner & Co., Netflix, 3M, Johnson & Johnson | Die Zollankündigungen von Donald Trump haben den deutschen Aktienmarkt weiter im Griff. Nach den Verlusten vom Montag gab der DAX auch gestern deutlich ab. Am Ende lag er 1,03 Prozent tiefer bei 24.703... ► Artikel lesen | |
| CG ONCOLOGY | 55,10 | +3,38 % | What Analysts Are Saying About CG Oncology Stock | ||
| PRAXIS PRECISION MEDICINES | 314,75 | +7,04 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| ADMA BIOLOGICS | 16,580 | -2,24 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| ARCELLX | 68,51 | -0,06 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ERASCA | 10,500 | +9,32 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| NUVALENT | 106,45 | +0,42 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 89,51 | -0,16 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| COGENT BIOSCIENCES | 38,500 | +1,69 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,600 | +0,22 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 15,470 | +3,06 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 29,360 | +4,78 % | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | - Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -
- Presenting at the 44th Annual J.P. Morgan... ► Artikel lesen | |
| UPSTREAM BIO | 32,500 | +7,76 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,700 | -0,81 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway |
ADALTA LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,002 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADALTA LIMITED finden Sie auf Wallstreet Online.